M2Bio Sciences Appoints Dr. Riyad Domingo as Chief Innovation Officer
Wuhan General Group, Inc. (OTC PINK: WUHN) has appointed Dr. Riyad Domingo as Chief Innovation Officer, effective immediately. Dr. Domingo holds a PhD in Medical Biochemistry and is known for founding a prominent medical device company. He brings extensive experience in healthcare innovation and partnerships with multinational firms. His role will focus on advancing product innovation, particularly in FDA Breakthrough Therapy status alkaloids. Dr. Domingo expressed enthusiasm for tackling mental health challenges post-COVID and aims to enhance drug discovery in psilocybin and related compounds.
- Appointment of Dr. Riyad Domingo as Chief Innovation Officer brings expertise in drug discovery and healthcare innovation.
- Dr. Domingo's background includes significant achievements in medical device manufacturing and international recognition.
- Focus on developing therapies for mental health issues and alcohol addiction aligns with growing market needs.
- Potential concerns regarding the continuity and experience gaps due to new management.
- Dr. Domingo's future engagement in academia might divert focus from the company's immediate operational needs.
CAPE TOWN, SA / ACCESSWIRE / September 2, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following remarkable update:
M2Bio SciencesTM is delighted to announce the appointment of
Dr. Riyad Domingo as Chief Innovation Officer effective immediately.
Dr. Domingo holds a PhD in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town. He is also the founder of SOUTH AFRICA MAKES, an award-winning and internationally recognized medical device digital manufacturing company, that has been featured on TEDx, brand eins, and Fast Company's Most Innovative Companies for 2021 in South Africa.
As an expert in healthcare innovation, Dr. Domingo has advised and partnered with numerous multinational companies, public-private partnerships, and development organizations. He has also been invited to present at numerous prestigious peer-reviewed conferences around the world including "Global Challenges in the 21st Century", "Future-proofing Africa for the Fourth Industrial Revolution" on behalf of the United States Consulate General in Cape Town, and most recently "Healthcare by Design" with the Kingdom of the Netherlands in South Africa.
In addition, Dr. Domingo has been selected as a Harvard South Africa Fellow for 2021-2022 to attend Harvard Business School in the fall. In the past, he has received numerous awards from the Department of Science and Technology, National Research Foundation, Medical Research Council, and the Oppenheimer Memorial Trust.
With extensive experience in the pharmaceutical and biotechnology industries, Dr. Domingo will be in charge of managing the process of continual innovation within the company to identify new products, technologies, capabilities, strategies, business opportunities, business models, and industry structures to serve those opportunities. He is particularly excited about the opportunity to work in the emerging field of alkaloids that have been granted FDA Breakthrough Therapy status.
"As we struggle to escape the grasp of one pandemic, we will be heading into another - mental illness. With the loss of self, loved ones, and our way of life, we have all been struggling to adjust to the post-COVID-19 world. Jeff and the team at M2Bio Sciences have some amazing and innovative achievements in their corner, and I am humbled to join the executive team and support the next phase of their growth. I look forward to leveraging my deep understanding of the drug discovery and development process to explore psilocybin, new tryptophan derivatives, and alternative methods of delivery of these compounds so that we not only create value for investors and shareholders, but also improve the quality of life for patients and other beneficiaries around the world." said Dr. Domingo.
M2Bio Sciences CEO Jeff Robinson, said, "I am enchanted that Riyad has agreed to come onboard as our CINO and to be an integral part of our Executive Leadership team. His academic and personal achievements are exemplary to say the least. This is a great step for M2Bio as we move forward and Riyad will play a very key role in supporting M2Bio's growth and long-term success. Another great win for the M2Bio team.''
"Dr. Domingo will be hosting a public webinar on the future of psychedelic drug discovery and research and its critical importance in the next century."
About Wuhan General Group, Inc./ M2Bio Sciences, Inc.
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™, and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
For further information:
Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/662512/M2Bio-Sciences-Appoints-Dr-Riyad-Domingo-as-Chief-Innovation-Officer
FAQ
Who is Dr. Riyad Domingo?
What are Dr. Domingo's qualifications?
What is the focus of Wuhan General Group under Dr. Domingo?
How might Dr. Domingo's appointment impact WUHN's stock?
What initiatives is Dr. Domingo planning for mental health?
